Amendment to the Claims

The claimed invention is:

1. (Currently Amended) A compound of formula (Ia), (Ib), or (Ic):



(Ia)



(Ib)



(Ic)

or a pharmaceutically acceptable salt, ~~prodrug~~, tautomer, hydrate or ~~solvate~~ thereof, wherein:

R^1 is a group of the formula



wherein R^1 can optionally be further independently substituted with at least one moiety independently selected from the group consisting of: carbonyl, halo, halo(C_1-C_6)alkyl, perhalo(C_1-C_6)alkyl, perhalo(C_1-C_6)alkoxy, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, hydroxy, oxo, mercapto, (C_1-C_6)alkylthio, (C_1-C_6)alkoxy, (C_5-C_{10})aryl ~~or (C_5-C_{10})heteroaryl~~, (C_5-C_{10})aryloxy ~~or (C_5-C_{10})heteroaryloxy~~, (C_5-C_{10})ar(C_1-C_6)alkyl ~~or (C_5-C_{10})heteroar(C_1-C_6)alkyl~~,

$(C_5\text{-}C_{10})$ar$(C_1\text{-}C_6)$alkoxy ~~or $(C_5\text{-}C_{10})$heteroar$(C_1\text{-}C_6)$alkoxy~~, HO-(C=O)-, ester, amido, ether, amino, amino$(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkylamino$(C_1\text{-}C_6)$alkyl, di$(C_1\text{-}C_6)$alkylamino$(C_1\text{-}C_6)$alkyl, ~~$(C_5\text{-}C_{10})$heterocyclyl$(C_1\text{-}C_6)$alkyl~~, $(C_1\text{-}C_6)$alkyl- and di$(C_1\text{-}C_6)$alkylamino, cyano, nitro, carbamoyl, $(C_1\text{-}C_6)$alkylcarbonyl, $(C_1\text{-}C_6)$alkoxycarbonyl, $(C_1\text{-}C_6)$alkylaminocarbonyl, di$(C_1\text{-}C_6)$alkylaminocarbonyl, $(C_5\text{-}C_{10})$arylcarbonyl, $(C_5\text{-}C_{10})$aryloxycarbonyl, $(C_1\text{-}C_6)$alkylsulfonyl, and $(C_5\text{-}C_{10})$arylsulfonyl;

each R^3 is independently selected from the group consisting of: hydrogen, halo, halo$(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, perhalo$(C_1\text{-}C_6)$alkyl, phenyl, $(C_3\text{-}C_{10})$cycloalkyl, hydroxy, $(C_1\text{-}C_6)$alkoxy, perhalo$(C_1\text{-}C_6)$alkoxy, phenoxy, $(C_3\text{-}C_{10})$cycloalkyl-O-, $(C_1\text{-}C_6)$alkyl-S-, $(C_1\text{-}C_6)$alkyl-SO_2-, $(C_1\text{-}C_6)$alkyl-NH-SO_2-, O_2N-, NC-, amino, $Ph(CH_2)_{1\text{-}6}HN$-, $(C_1\text{-}C_6)$alkyl HN-, $(C_1\text{-}C_6)$alkylamino, $[(C_1\text{-}C_6)\text{alkyl}]_2$-amino, $(C_1\text{-}C_6)$alkyl-SO_2-NH-, amino(C=O)-, aminoO_2S-, $(C_1\text{-}C_6)$alkyl-(C=O)-NH-, $(C_1\text{-}C_6)$alkyl-(C=O)-[(($(C_1\text{-}C_6)$alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[($(C_1\text{-}C_6)$alkyl)-N]-, $(C_1\text{-}C_6)$alkyl-(C=O)-, phenyl-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl-(C=O)-, HO-(C=O)-, $(C_1\text{-}C_6)$alkyl-O-(C=O)-, H_2N(C=O)-, $(C_1\text{-}C_6)$alkyl-NH-(C=O)-, $[(C_1\text{-}C_6)\text{alkyl}]_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[(($C_1\text{-}C_6$)alkyl)-N]-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl-NH-(C=O)- and $(C_1\text{-}C_6)$alkyl-(C=O)-O-;

where alkyl, alkenyl, alkynyl, phenyl, cycloalkyl, alkoxy, phenoxy, amino of R^3 is optionally substituted by at least one substituent independently selected from $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, halo$(C_1\text{-}C_6)$alkyl, halo, H_2N-, $Ph(CH_2)_{1\text{-}6}HN$-, and $(C_1\text{-}C_6)$alkylHN-;

s is an integer from one to five;

and

R^6 is selected from the group consisting of hydrogen, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, phenyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_1\text{-}C_6)$alkyl-(SO_2)-, phenyl-(SO_2)-, H_2N-(SO_2)-, $(C_1\text{-}C_6)$alkyl-NH-(SO_2)-, $((C_1\text{-}C_6)\text{alkyl})_2N$-$(SO_2)$-, phenyl-NH-$(SO_2)$-, $(\text{phenyl})_2N$-(SO_2)-, $(C_1\text{-}C_6)$alkyl-(C=O)-, phenyl-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl-(C=O)-, $(C_1\text{-}C_6)$alkyl-O-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl-O-(C=O)-, H_2N-(C=O)-, $(C_1\text{-}C_6)$alkyl-NH-(C=O)-, phenyl-NH-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl-NH-(C=O)-, $((C_1\text{-}C_6)\text{alkyl})_2N$-(C=O)-, $(\text{phenyl})_2N$-(C=O)-, phenyl-[(($C_1\text{-}C_6$)alkyl)-N]-(C=O)-,

and $(C_3$-$C_{10})$cycloalkyl-[$((C_1$-$C_6)$alkyl)-N]-(C=O)-;

where alkyl, alkenyl, alkynyl, phenyl, benzyl, cycloalkyl, alkoxy, phenoxy, amino of R^6 is optionally substituted with at least one moiety independently selected from the group consisting of halo, $(C_1$-$C_6)$alkyl,
$(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, perhalo$(C_1$-$C_6)$alkyl, $(C_3$-$C_{10})$cycloalkyl, phenyl, benzyl, ~~$(C_5$-$C_{10})$heterocyclic, $(C_5$-$C_{10})$heteroaryl~~, $(C_1$-$C_6)$alkyl-SO_2-, formyl, NC-,
$(C_1$-$C_6)$alkyl-(C=O)-, (C_3C_{10})cycloalkyl-(C=O)-, phenyl-(C=O)-,
~~$(C_5$-$C_{10})$heterocyclic-(C=O)-, $(C_5$-$C_{10})$heteroaryl-(C=O)-~~, HO-(C=O)-,
$(C_1$-$C_6)$alkyl-O-(C=O)-, $(C_3$-$C_{10})$cycloalkyl-O-(C=O)-,
~~$(C_5$-$C_{10})$heterocyclic-O-(C=O)-~~, $(C_1$-$C_6)$alkyl-NH-(C=O)-,
$(C_3$-$C_{10})$cycloalkyl-NH-(C=O)-, phenyl-NH-(C=O)-,
~~$(C_5$-$C_{10})$heterocyclic-NH-(C=O)-, $(C_5$-$C_{10})$heteroaryl-NH-(C=O)-~~,
$((C_1$-$C_6)$alkyl$)_2$-N-(C=O)-, phenyl-[$((C_1$-$C_6)$alkyl)-N]-(C=O)-, hydroxy,
$(C_1$-$C_6)$alkoxy, perhalo$(C_1$-$C_6)$alkoxy, $(C_3$-$C_{10})$cycloalkyl-O-, phenoxy,
~~$(C_5$-$C_{10})$heterocyclic-O-, $(C_5$-$C_{10})$heteroaryl-O-~~, $(C_1$-$C_6)$alkyl-(C=O)-O-,
$(C_3$-$C_{10})$cycloalkyl-(C=O)-O-, phenyl-(C=O)-O-, ~~$(C_5$-$C_{10})$heterocyclic-(C=O)-O-, $(C_5$-$C_{10})$heteroaryl-(C=O)-O-~~, O_2N-, amino, $(C_1$-$C_6)$alkylamino,
$((C_1$-$C_6)$alkyl$)_2$-amino, formamidyl, $(C_1$-$C_6)$alkyl-(C=O)-NH-,
$(C_3$-$C_{10})$cycloalkyl-(C=O)-NH-, phenyl-(C=O)-NH-,
~~$(C_5$-$C_{10})$heterocyclic-(C=O)-NH-, $(C_5$-$C_{10})$heteroaryl-(C=O)-NH-~~,
$(C_1$-$C_6)$alkyl-(C=O)-[$((C_1$-$C_6)$alkyl)-N]-, phenyl-(C=O)-[$(C_1$-$C_6)$alkyl-N]-,
$(C_1$-$C_6)$alkyl-SO_2NH-, $(C_3$-$C_{10})$cycloalkyl-SO_2NH-, phenyl-SO_2NH-,
~~$(C_5$-$C_{10})$heterocyclic-SO_2NH- and $(C_5$-$C_{10})$heteroaryl-SO_2NH-~~;

wherein the phenyl moiety of a R^6 substituent is optionally further substituted with at least one radical independently selected from the group consisting of halo, $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, perfluoro$(C_1$-$C_6)$alkyl and perfluoro$(C_1$-$C_6)$alkoxy.

2. (Previously Cancelled)

3. (Previously Cancelled)

4. (Previously Cancelled)

5. (Previously Cancelled)

6. (Previously Cancelled)

7. (Previously Cancelled)

8. (Previously Cancelled)

9. (Original) A compound of claim 1, wherein s is one to two; R^3 is hydrogen or (C_1-C_6)alkyl; and R^6 is H, (C_1-C_6)alkyl, or (C_3-C_{10})cycloalkyl.

10. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

11. (Cancelled)

12. (Cancelled)

13. (Previously Presented) A compound 6-[5-(6-methyl-pyridin-2-yl)-2H-[1,2,3] triazol-4-yl]-quinazoline or a pharmaceutically acceptable salt thereof.

14. (Previously Presented) A pharmaceutical composition comprising 6-[5-(6-methyl-pyridin-2-yl)-2H-[1,2,3] triazol-4-yl]-quinazoline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.